Point2 About ASKA - Our Strengths -

Value Creation Model Driven by Expertise in the Hormone Field

Under its Purpose, “Tomorrow and Beyond, Healthy for All Life,” ASKA Pharmaceutical Holdings Group creates value by leveraging the expertise in the hormone field and strengths in specialty areas that it has cultivated over more than 100 years. Building on its core competencies, namely highly skilled people and organizational capabilities, trusted relationships with stakeholders, and a strong presence in specialty fields, the Group is advancing five growth-driving businesses: Domestic Prescription Pharmaceuticals, Drug Discovery, Global Business, Animal Health, and Diagnostics & Around-the-Pill Solutions.
Drawing on the expertise and customer base developed through its Domestic Prescription Pharmaceuticals business, the Group is expanding its business portfolio through the creation of new value in drug discovery, global expansion centered on Asia, applications in the animal health field, and total healthcare solutions encompassing diagnostics, testing, and prognostic care. Through synergies among these businesses, the Group seeks to address social challenges and achieve sustainable growth, with the goal of becoming a globally recognized specialty healthcare company creating value worldwide by 2035.

Healthcare for women

• A leading company in the Ob/Gyn field
• Top sales in the Ob/Gyn field (In-house estimate for FY2025)

Endocrine hormones

• Endocrine hormone R&D Over 100 years
• A leading company in the thyroid field
• 95% share of domestic market
  
  

Global

• Expanding business operations across Southeast Asia, with a focus on Vietnam and the Philippines
• Strengthening supply capabilities through the utilization of Hataphar’s new manufacturing facility
• Providing products tailored to local market needs

Animal Health

• Large market presence in the livestock field thanks to lineup of mainstay breeding hormone preparations
• Products addressing untapped needs in the companion animal market
• Contribution to greater uptake of low-protein feed through full lineup of feed-use amino acids

Microdetermination (non-invasive testing)

• High-sensitivity measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
• Multi-item simultaneous steroid hormone measurement
• Ultra-high-sensitive estrogen measurement
• Measurement of thyroid-related substances
• Measurements using non-invasive samples

Optimal Value Chain Derived from DNA Rooted in Corporate Culture

A value chain penetrated with DNA is the source of ASKA Pharmaceutical's impressive growth.

ASKA Pharmaceutical's DNA is "As a pioneer of hormone preparations, we have a mission to deliver valuable pharmaceutical products as long as there is a medical need for them. In the past, present, and future, this DNA has taken root in each employee in our value chain (research, development, sales, production, quality assurance, etc.). It drives us to take on the challenge of meeting medical needs. Every one of our employees will keep this DNA in their hearts as their strength, aiming to create the value that only ASKA Pharmaceutical can offer.

Contribution to the Obstetrics and Gynecology Field

Supporting the vibrant advancement of women by contributing to the field of obstetrics and gynecology

We pharmaceutical companies face various challenges in the environment surrounding us, such as the declining birthrate and aging population, promotion of women's activities, expansion of medical expenses, and response to unmet medical needs*. Amid these challenges, ASKA Pharmaceutical, as a pioneer of hormone preparations, fulfills its mission by leveraging its presence in the field of obstetrics and gynecology, which it has developed over the years, to enhance its presence as a specialty pharma company that supports the improvement of the quality of life (QOL) of women in particular.

*Unmet medical needs = medical needs that have not yet been met